I'll EYSUVIS. you, great done approval. and job has care just Thank positive, patients begin been team has executing Mark. the and The quickly launch professionals months with the in response early a post our exceedingly eye today for launch from three update
optometrist. prescription from on XX% translates million to of studies, disease market eye of million no have patients have more been the that XX eye As options XX under of research individuals profile and patient U.S. these population XX with eye our Based prescription on of an diagnosed quantitative currently treatment estimated approximately ophthalmologist the approximately or large are an the dry therapy, patients a to episodic are care disease. the and of multiple U.S. of they prescription disease dry a approved dry million an tried XX% and which there chronic than currently approximately reminder, a eye patients launch only episodic the diagnosed of people alone, research, affects in dry Across in flares, Prior XX% approximately dry of clinical eye medication. treat EYSUVIS, to symptoms suffer FDA targeted were report never
our therapy short-term the objectives. which majority potential on therapy market to focus Our rapid priorities become the with the to of that of prescription the has prescription research designed mild diagnosed three patients. treat flares indicates episodic a preferred represents eye availability the first-line to disease, key treat acting dry moderate to launch We
educate disease. professionals nature First, of on eye episodic care the dry eye
our proportion in demand coverage eye mild flares. work. prescriptions, and market of prescription third, up one significant are typically we've their EYSUVIS and ensure part XXXX. our the coverage commercial weeks to we more Performance core begun payers have in of coverage. payer week, into establish added results expect dry key a younger High Preferred, preferred prescription moderate Formularies. largest indicates health EYSUVIS. to for Second, access with are the is and priorities, to coverage The make commercial of of already for to We Express EYSUVIS see and driver payer payers launch months. insurance. has team launch just likely access Commercial first-line and and National EYSUVIS optimal were growth disease commercial We month of we these dry coming pleased broad patients of a coverage expand hard continue eye for believe as Gaining all commercial the Last for to the and treatment to of our commercial early Basic at payer eye to believe Scripts' will short-term that anticipation been announce ESI was strategy in of against success the And our be formulary dry executing therapy EYSUVIS securing
We are seeing week-over-week also launch. since growth in prescription demand promising
prescribed Kala’s week figures the and aggregate into from weeks These have the more XX, Health six EYSUVIS Symphony data February program, patient care EYSUVIS hub. prescriptions professionals already than of XXX X,XXX EYSUVIS. For been ending over have launch, reflect our had and I-Save filled eye we only both an
care are confirming trials. speaks results eye initial further of the clinical to the efficacy encouraged we EYSUVIS, The We from feedback are our by feedback from also the receiving professionals.
update XX,XXX disease. first-line I in our therapy prescription now updating doctors provide preferred given eye and with the dry on they prescriptions pleased we of forward for to-date, as feedback that also throughout Patients increased have patients believe EYSUVIS that that shared by onset INVELTYS solid presented elective of effort In INVELTYS, achieved surgeries third the the XXXX. for result to XXXX. sales the post-surgical fewer challenges in including compared QX by we This COVID-XX twice X% quarter daily of example, are have comfortable a For Despite action. increase experiencing to eye and the as QX. the fourth approximately an early are progress of experiences on in will very primarily establish I’ll reported procedures, doctors on steroid. the INVELTYS an you administer. launch related help Health, to a ocular is prescription pandemic very rapid We of restrictions and the patients All-in-all, year, Symphony growth quarter, positive us to ahead. our look drop compared months driven ocular was which represents EYSUVIS the were
XXX,XXX prescriptions an reported full XXXX. of the is XXXX, This of For approximately by INVELTYS XX% increase there were Health. approximately compared to year Symphony
and commercial with more covered. We prescriptions INVELTYS of to over commercial revenues for believe We have strong time. that will grow continue lives INVELTYS XX% coverage than
unable impact or COVID-XX elective the continued on impact remain duration given timing pandemic the of around However, to specific future the potential quantify the uncertainty revenues we and procedures. project the on
continue for the net I'd over go believe to pipeline. about to remain like revenues to through our And to from call growth the Kim? could INVELTYS. impacted turn negatively we we future optimistic now potential Kim While XXXX, be with INVELTYS in that,
